Business context and reporting period
Nyxoah SA, a medical technology company, furnished this Form 6-K for September 2026. The filing reports a chief executive transition intended to further accelerate the company’s U.S. commercial traction.
Management transition
- Liam Kelly was appointed Chief Executive Officer effective October 1, 2026, succeeding Olivier Taelman.
- Kelly previously served as Chairman, President and CEO of Teleflex Incorporated, and held senior roles at Teleflex and Hill-Rom. He is also a director of Enovis Corporation.
- Nyxoah had announced the start of its leadership transition process on June 4, 2026. Taelman signed this Form 6-K on September 29 as CEO.
Financial performance and outlook
This filing provides no revenue, earnings, cash flow, margin, debt, liquidity, or other operating metrics, and gives no financial guidance or quantified outlook.
Investor facts to verify
- Confirm the CEO appointment took effect on October 1, 2026.
- Review the September 28 press release identified as Exhibit 99.1 for any additional transition details; its contents are not included in the supplied filing text.
- Track subsequent disclosures for evidence of changes to U.S. commercial execution or financial outlook.